Get access to more insightful information

By signing up to Upstox today
Shareholding Info
  • Promoters
    54.48 %
  • Foreign institutions-FII
    16.48 %
  • Other domestic institutions
    6.59 %
  • Retail and other
    9.29 %
  • Mutual Funds
    13.16 %

About Sun Pharma

Sun Pharmaceutical Industries Limited (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, the company provides high-quality and affordable medicines to more than 100 countries across the globe. The company was incorporated in 1983 and employs more than 37,000 individuals worldwide. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Their portfolio has more than 2000 high quality molecules covering multiple dosage forms like tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Every year, it sells over 30 billion doses in the neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory sectors.The company invests up to 7-8% of its global revenues into Research and Development (R&D) every year and has a strong team of more than 2000 scientists.

Core Activities & Products

  1. Speciality Medications :Sun Pharma has a portfolio of patent protected speciality medicines for global markets. The company targets key segments like dermatology, ophthalmology and oncology. It focuses on improving patient outcomes either by addressing unmet medical needs or by enhancing patient convenience through differentiated dosage forms. The company’s initiatives in this segment cover the entire value chain, from in-licensing early-to-late stage clinical candidates, as well as getting access to on-market patented products. It is one of the leading branded companies in the US with several specialty products launched in the country.
  2. Generic Medications: The company’s products cover the full range of dosage forms including tablets, capsules, injectables, inhalers, ointments, creams and liquids. In these therapy areas, Sun Pharma ranks as a leading company in many countries.
  3. Over-the-Counter Medications:The company provides a range of over-the-counter (OTC) and consumer healthcare products. Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are a few of their flagship OTC brands. Other brands include Coldact & Flustat (cold & flu), Brustan, Painamol & Paduden (analgesics), Aspenter, Aspacardin, Nudrate & Fortifikat (lifestyle OTCs), Gestid (digestives) and Chericof (cough).
  4. Active Pharmaceutical Ingredients :The company produces more than 300 types of APIs. Their product list includes generics and complex APIs that require isolated manufacturing areas like anti-cancers, peptides, steroids, sex hormones and controlled substances, including poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics, sold as both Narcotic Raw Materials (NRM) and APIs. It also offers bulk actives, intermediates and services for custom synthesis.
  5. Antiretroviral Medications:The company offers a wide range of WHO prequalified ARV medicines. The company’s portfolio comprises bio-equivalent ARV medicines and Active Pharmaceutical Ingredients (API). They also offer several first-line and second line Highly Active Antiretroviral Therapy (HAART) regimens.

Board of Directors

  • Chairman, Non-Executive and Non-Independent Director: Israel Makov
  • Managing Director: Dilip S. Shanghvi
  • Non-Executive and Independent Director: Rama Bijapurkar
  • Non-Executive and Non-Independent Director: Sudhir V. Valia
  • Non-Executive and Lead Independent Director: Dr. Pawan Goenka
  • Non-Executive and Independent Director: Gautam Doshi
  • Whole-time Director: Sailesh T. Desai
  • Whole-time Director: Kalyanasundaram Subramanian

Key Executives

  • CEO - North America: Abhay Gandhi
  • Senior Vice-President, Head of Human Resources: Dr. Sapna Purohit
  • Whole-time Director and Director - Corporate Development: S. Kalyanasundaram
  • Executive Vice-President, Head - Emerging Markets Head - Global Generics R&D and Business Development: Aalok Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • Executive Vice-President, Global Head - Quality: Jila Breeze
  • Senior Vice-President, Chief Information Officer (w.e.f. June 20, 2022): Anil Rao
  • CEO - India Business: Kirti Ganorkar
  • Business Head - Western Europe, Australia and New Zealand: Hellen de Kloet
  • Senior Vice-President, Corporate Relations and CSR, India Regulatory Affairs: Dr. Azadar H. Khan
  • CEO - Taro Pharmaceutical Industries Ltd.: Uday Baldota
  • Senior Vice-President, Head - Global Supply Chain: Sreenivas Rao
  • Executive Vice-President, Sun Global Operations: Davinder Singh


  • Sun Pharma is a leading generic pharmaceutical company in the world and the largest pharmaceutical company in India.
  • In the US, the company is among the top 10 generic pharmaceutical companies and is ranked second by prescriptions in the generic dermatology market.
  • It is also the largest Indian company in emerging markets with a presence in over 80 of them. Brazil, Mexico, Russia, Romania and South Africa are some of its key emerging markets.
  • They are also present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others. The company’s presence in emerging markets and the developing world enables its teams to cross-sell and build brands with ease.
  • The company has a global manufacturing presence comprising 43 manufacturing facilities across India, the Americas, Asia, Africa, Australia and Europe.
  • It is amongst top 10 consumer healthcare companies in India, Romania, Nigeria & Myanmar.
  • It manufactures APIs in 14 manufacturing facilities located in India, Hungary, US, Israel and Australia.
  • ARV and API medicines are manufactured in India, South Africa and Russia.

Performance in Various Sectors

Out of the ₹332 billion sales in FY22, 31% came from India branded formulations, 30% came from US formulations, 18% came from emerging markets, 15% came from rest of the world and 6% came from API and others.
  • US Business: The company ranked 2nd in the US dermatology market as per IQVIA data for 12 months ended in December 2021. Its portfolio consists of 600 ANDAs & 66 NDAs filed and 512 ANDAs & 53 NDAs approved across multiple therapies. US Business has seen a 16% growth in its sales on the basis of 10 year CAGR.
  • India Branded Generic Business: The company is at number one position with a 8.2% of market share. It is also a market leader in the chronic segment. Its 29 brands are present in the country’s top 300 pharmaceutical brands. This segment has also seen a 16% growth in its sales on the basis of 10 year CAGR.
  • Emerging Markets: The company is present in 80 markets with local manufacturing in 7 countries and a sales force of 2,200 representatives.
  • Rest of World: The company acquired Pola Pharma in Japan and 14 established prescription brands from Novartis. It launched Ilumya in Japan and Canada. It enjoys brand equity in 4 countries.
  • Active Pharmaceutical Ingredients Business: The company has a product portfolio of approximately 370 APIs with 20-30 APIs scaled up annually whose manufacturing takes place across 14 facilities.

CSR and Sustainability

The company’s CSR activities work for the betterment in the health, education, drinking water and sanitation areas.
  • Malaria Elimination: FDEC India was established by Sun Pharmaceutical Industries as a not-for-profit entity. Culminated in 2021, the MEDP achieved reduction of 91% in indigenous malaria cases in over 1200 villages of the Mandla district.
  • Mobile Healthcare Units:Mobile Healthcare Units (MHUs) deliver primary healthcare services to over 650,000 people located around areas close to the company’s manufacturing plants and other establishments. These MHUs serve a mix of rural and underserved populations and visit villages to provide treatment for common ailments, conduct pathological tests, enable referrals, and provide free medicines.
  • Model School Development: The company develops model schools in and around their served communities to enable and empower rural school students to access and enjoy equal educational and development opportunities.
  • Safe Drinking Water and Sanitation: The company provides access to clean drinking water in villages, constructs good quality individual toilets and implements effective behavior change programmes.
  • Sun Pharma Science Foundation: It is an independent non-profit organization dedicated to promoting scientific endeavors in India by encouraging and rewarding excellence in the medical and pharmaceutical sciences.
  • Environment, Health and Safety:The company’s EHS Policy provides for the creation of a safe and healthy workplace and a clean environment for all employees and served communities.


Reaching People And Touching Lives Globally As A Leading Provider Of Valued Medicines 


In May, 2022, an inspection by FDA had found 10 observations at the company’s Halol manufacturing facility in Gujarat, India and was given the Form 483. 
In October, 2021, the company had recalled 100,000+ bottles of generic tadalafil tablet distributed in the U.S. after an incorrect grade of an inactive ingredient was found to have been added during production. 
It had also recalled 22,752 blister packs because of failed moisture limits. 

Covid-19 Impact

Covid-19 had a positive impact on the company as it is a part of the pharmaceutical industry. Most of the company’s businesses recorded growth and its India business outperformed the average industry growth. All of the company's manufacturing plants operated continuously. It reported a 2.5% growth in its overall revenues which stood at ₹331 Billion for FY21. Its EBITDA also grew by 25.5% in FY21. 


Over the years, Federal Bank has grown into one of the country’s largest private sector banking institutions. This has been possible due to the various strengths that it possesses. Here’s a quick look at a few key strengths of the bank.
  1. The bank enjoys an exceptionally wide network with over 1,200 branches across the entire country.
  2. The entity has a high Return on Equity (ROE), which signifies that it uses shareholder’s funds effectively.
  3. The bank’s revenue and net profit have been on an increase year over year and have consistently beaten the market’s expectations.
  4. The entity enjoys an exceptionally large customer base of around 10 million.
  5. The bank’s marketing campaigns are highly innovative and help increase its customer base.

CSR and Sustainability

Ever since its inception, Federal Bank has consistently strived to empower the weaker sections of society through various measures. Apart from bringing the formal banking system to the underserved, the bank has also partaken in facilitating education, healthcare, and women empowerment. One of the many CSR activities undertaken by the company includes Project Sanjeevani in partnership with the N18 Group. Through this project, Federal Bank went on a drive to educate Indian citizens about the benefits of COVID-19 vaccination. Around Rs. 15.35 crores were spent on this initiative. Similarly, the bank also spent around Rs. 7.78 crores for COVID-19 vaccination in 5 districts and more than 1,000 villages in association with the United Way of Mumbai. Thanks to these two programmes, around 24.25 lakh individuals benefitted as a result. Apart from contributions towards the eradication of the COVID-19 pandemic, Federal Bank has also introduced Federal Bank Hormis Memorial Foundation Scholarships. Through these scholarships, the bank provides financial assistance to students from financially weaker sections of the society. The Federal Skill Academy at Kochi, Kerala, is another CSR initiative by the company. Through this programme, the unemployed youth from the underprivileged sections of the society are imparted skill training to increase their chances of getting employed. Around Rs. 15.98 crores were spent by Federal Bank towards improving the existing healthcare infrastructure in many parts of the country. As part of this particular initiative, the bank sponsored Trauma Care Units in Himachal Pradesh, a comprehensive centre for Cognitive Rehabilitation, and medical equipment for the Cardiology Unit in the Ernakulam General Hospital. In the financial year 2021-2022 alone, Federal Bank has spent around Rs. 40.06 crores towards Corporate Social Responsibility.

COVID-19 Impact

As with many other industries and sectors, the COVID-19 pandemic caused significant distress to the banking industry, including Federal Bank. Due to lockdowns essentially forcing many businesses on hold, there were considerable risks to the bank’s loan book due to doubts arising on borrowers’ debt servicing abilities. Also, due to the slowdown in economic growth, the bank’s gross Non Performing Assets (NPAs) saw an uptick from 2.84% in March, 2020 to around 3.41% in March, 2021. However, despite the rise in NPA, the bank’s net interest income rose from Rs. 4,649 crores in March, 2020 to Rs. 5,534 crores in March, 2021. To reduce the impact of COVID-19 on its business, Federal Bank focused on ensuring that its banking services continued to remain accessible to its customers. Although the bank’s digital footprint was already quite high compared to other banking institutions, many digital innovations were introduced to help customers continue their banking operations from the comfort of their own home.

Future Prospects

    US Business:
    • Enhance share of specialty/branded business
    • Continue to focus on complex generics and high entry barrier segments
    • Ensure broad product offering to customers across multiple dosage forms
    India Business:
    • Focus on productivity enhancement
    • Maintain leadership position in a fiercely competitive market
    • Continuously innovate to ensure high brand equity with doctors
    • Continue to evaluate in-licensing opportunities for latest generation patented products
    EM & RoW Business:
    • Gain critical mass in key markets
    • Enhance product basket in emerging markets
    • Focus on profitable growth
    Global Consumer Healthcare:
    • Maintain leadership in existing markets through focus on innovative solutions
    • Enhance presence in high growth markets
    • Committed to Governance, Community Upliftment, Access to Affordable Healthcare & Environment Conservation
    • Focus on developing complex products across multiple dosage forms
    • Invest to further build the specialty pipeline
    Regulatory/ Quality:
    • Focus on developing complex products across multiple dosage forms
    • Invest to further build the specialty pipeline
    • Target sustainable and profitable growth
    • Focus on improving overall return ratios

Did You Know!

  • Sun Pharma started out in 1983 with the establishment of five psychiatry products and a two-person marketing team.
  • Its first manufacturing facility for tablets and capsules was set up at Vapi in Gujarat, India.
  • The company established its first research center in 1991.
  • The company was listed in Forbes five times.
  • Sun Pharma supplies ARVs to various National AIDS treatment programs in Africa.
  • In 2004, the company signed up with the Clinton Health Access Initiative (CHAI) to help reduce the cost of the triple drug cocktail for consortium partners in Africa and other countries.

Initial Public Offering

Sun Pharma’s IPO was launched in December 1994 with an issue price of ₹150. It was listed in 1995 for the price of ₹220. The IPO was oversubscribed 55 times. Its shares are available on both BSE and NSE.

Equity Shares

Of the total 2,39,93,34,970 paid up equity shares, promoter and promoter group owns 1,30,71,34,535 shares and the public owns 1,09,22,00,435 shares making up 54% and 46% respectively. Of the total 6,47,167 shareholders, 14 are promoter and promoter group and 6,47,153 are the public.
Download Icon Download the Upstox App Today

Download Upstox Mobile App